世界における抗体薬物複合体(ADC)のパイプライン分析2015

◆英語タイトル:Antibody-Drug Conjugate (ADC)- Pipeline Insights, 2015
◆商品コード:DELV51104
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2015年版(※最新版はお問い合わせください)
◆ページ数:※お問い合わせください。
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User USD1,950 ⇒換算¥214,500見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD3,900 ⇒換算¥429,000見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD5,500 ⇒換算¥605,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
DelveInsight’s, Antibody-Drug Conjugate (ADC)- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Antibody-Drug Conjugate (ADC). The report provides insights on around 200+ products and 160+ different Companies, which are active in this field. The report also throws the light on 60+ different technologies used by the companies for ADCs development. The main objective of this report is to track competitor’s pipeline molecules, related research activities, technologies, collaborations, funding and licensing activities.. The Antibody-Drug Conjugate (ADC) Report helps to identify emerging players with potentially strong product information and to create effective counter-strategies to gain competitive advantage.

DelveInsight’s, Antibody-Drug Conjugate (ADC)-Pipeline Insights, 2015 Report covers the Antibody-Drug Conjugate (ADC) pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. The Report also highlights the discontinued and inactive projects in pipeline for Antibody-Drug Conjugate (ADC).

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


Scope
• DelveInsight’s report provides an Antibody-Drug Conjugate (ADC) Landscape across the globe
• The report provides drug profiles which includes product description, MOA, licensors & collaborators, technology, development partner and chemical information
• Coverage of the Antibody-Drug Conjugate (ADC) pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Antibody-Drug Conjugate (ADC) and also provide company profiling
• Pipeline products coverage based on various stages of development from NDA filings to discovery
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


【レポートの目次】

•Antibody-Drug Conjugate (ADC) Overview
• Antibody-Drug Conjugate (ADC) Pipeline Therapeutics
• Antibody-Drug Conjugate (ADC) Therapeutics under Development by Companies
• Antibody-Drug Conjugate (ADC) Late Stage Products (Filed and Phase III)
• Comparative Analysis
• Antibody-Drug Conjugate (ADC) Mid Clinical Stage Products (Phase II)
• Comparative Analysis
• Antibody-Drug Conjugate (ADC) Early Clinical Stage Products (Phase I and IND Filed)
• Comparative Analysis
• Antibody-Drug Conjugate (ADC) Discovery and Pre-Clinical Stage Products
• Comparative Analysis
• Drug Candidate Profiles
• Antibody-Drug Conjugate (ADC)– Discontinued Products
• Antibody-Drug Conjugate (ADC) – Dormant Products
• Appendix
• Methodology
• Contact Us
• Disclaimer

List of Tables
•Number of Products under Development for Antibody-Drug Conjugate (ADC), 2015
• Number of Products under Development by Companies
• Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2015
• Comparative Analysis mid Clinical Stage Products (Phase II), 2015
• Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2015
• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2015
• Drug Candidates Profiles
Antibody-Drug Conjugate (ADC) Therapeutics – Discontinued Products
• Antibody-Drug Conjugate (ADC) Therapeutics – Dormant Products
• Products under Development by Companies, 2015



【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界における抗体薬物複合体(ADC)のパイプライン分析2015(Antibody-Drug Conjugate (ADC)- Pipeline Insights, 2015)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆